Market access professionals are gearing up to battle it out for the ‘National Market Access Lead of the Year’ in the upcoming PharmaTimes Marketer of the Year competition.
News
US regulators wave through Pfizer’s leukaemia drug
The US Food and Drug Administration has approved Pfizer’s Besponsa, the first and only CD22-directed antibody-drug conjugate indicated to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
MHRA OK’s psoriasis cream switch to OTC
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved the switch of Dovonex Psoriasis Ointment from a prescription-only drug to one available in pharmacies
FDA expands use of AZ/Merck’s Lynparza in the US
AstraZeneca and Merck & Co’s Lynparza will be available to a wider range of patients in the US after regulators expanded the PARP inhibitor’s list of approved uses.
Gov’t streams £5m into obesity research unit
The Department of Health has announced £5 million of funding for a new obesity policy research unit at University College London, alongside plans to cut calories in some foods to reign in the rising trend of childhood obesity.
Global COPD deaths up 12 percent in 15 years
The number of people dying from chronic obstructive pulmonary disease has climbed nearly 12 percent over a 15-year period, an analysis for the Global Burden of Disease Study 2015 has found.
Novo’s semaglutide superior to Lilly’s Trulicity in diabetes trial
Novo Nordisk’s once-weekly diabetes drug semaglutide has beaten Eli Lilly’s once-weekly therapy dulaglutide on reducing blood sugar and weight in patients taking part in a late-stage trial.
CR UK, Newcastle Uni extend alliance with Astex
Cancer Research UK and Newcastle University have extended their strategic drug discovery alliance with Astex Pharmaceuticals by three years to work on developing new cancer drugs and associated biomarkers.
Just two-thirds of trainee GPs plan career in NHS general practice
Only two in three doctors who are completing their training to become GPs plan to work in NHS general practice, research by the University of Warwick has found.
Health officials urge young people to get meningitis jab
Public Health England and the Royal College of Nursing are urging new university students to get vaccinated against meningitis so that they can build immunity to the disease before fresher’s week, after figures show that uptake of the jab last year was low.
Vectura allows Dynavax access to smart inhalers
Vectura has signed an exclusive global agreement with Dynavax Technologies allowing use of its proprietary smart nebuliser technology to deliver an investigational immunotherapeutic to lung cancer patients.
GSK opens new aluminium salts facility in Scotland
GlaxoSmithKline has officially opened a new £44 million aluminium salts facility in Montrose, Scotland, which is set to supply ingredients for around 400 million vaccines a year.
Mixed results for BMS’ Opdivo, Yervoy combo in kidney cancer
A combination of Bristol-Myers Squibb’s Opdivo and Yervoy has failed to significantly improve progression-free survival (PFS) compared to Pfizer’s Sutent in patients with renal cancer.
Regeneron drops RSV therapy on trial failure
Regeneron Pharmaceuticals is pulling the plug on an experimental therapy in development for preventing respiratory syncytial virus (RSV) infection in infants, after a disappointing performance in a late-stage trial.
